Pentamidine: A Non-Peptide GPIIb/IIIa Antagonist – In Vitro Studies on Platelets from Humans and Other Species

Author:

Cox Dermot1,Motoyama Yukio1,Seki Jiro1,Aoki Toshiaki1,Dohi Miwako1,Yoshida Keizo1

Affiliation:

1. The New Drug Research Laboratories, Fujisawa Pharmaceutical Company, Osaka, Japan

Abstract

SummaryIn this paper we show that the non-peptide anti-parasite agent pentamidine is a broad spectrum anti-platelet agent with an IC50 of 1.1 µM in ADP-induced platelet aggregation in human platelet rich plasma (PRP). It had similar activity when collagen, arachidonic acid, platelet activating factor, thrombin and epinephrine were used. It had no effect on platelet intracellular cAMP levels. It inhibited 125I-fibrinogen, 125I-fibronectin and 125I-von Willebrand factor binding to ADP-activated fixed platelets with IC50 values of 160, 160 and 60 nM respectively. Pentamidine showed a high degree of species selectivity with slightly less activity in monkey and dog PRP and little activity in guinea pig, rabbit, rat and mouse PRP compared with human. This was similar to the other RGD analogues tested. This species specificity was shown to be dependent on the species of platelets and independent of the species of fibrinogen. Thus, pentamidine is a potent non-peptide inhibitor of fibrinogen binding to GPIIb/IIIa.

Publisher

Georg Thieme Verlag KG

Subject

Hematology

Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Blood Constituents and Safety Pharmacology: In Vitro and In Vivo Thrombosis and Hemostasis Assays;Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays;2022

2. Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug;PLOS Neglected Tropical Diseases;2021-04-15

3. Integrins as Drug Targets: Is There a Future?;Encyclopedia of Molecular Pharmacology;2021

4. Integrins as Drug Targets: Is There a Future?;Encyclopedia of Molecular Pharmacology;2021

5. How not to discover a drug - integrins;Expert Opinion on Drug Discovery;2020-09-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3